Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 7/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9645312 | 0.81 | ALOX5 (0.69) | ALOX5 | |
| SCHEMBL9645323 | 0.81 | ALOX5 (1.00) | ALOX5 | |
| SCHEMBL9645372 | 0.80 | ALOX5 (0.71) | ALOX5 | |
| SCHEMBL9644564 | 0.80 | ALOX5 (1.00) | ALOX5 | |
| SCHEMBL9645332 | 0.80 | ALOX5 (0.70) | ALOX5 | |
| SCHEMBL9645227 | 0.78 | ALOX5 (1.00) | ALOX5 | |
| SCHEMBL9645254 | 0.77 | ALOX5 (0.67) | ALOX5 | |
| SCHEMBL9645311 | 0.77 | ALOX5 (0.62) | ALOX5 | |
| SCHEMBL9645304 | 0.76 | ALOX5 (1.00) | ALOX5 | |
| SCHEMBL9645445 | 0.76 | ALOX5 (0.68) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4970210-A | ENZYME INHIBITORS | ABBOTT LABORATORIES (US) | 1990-11-13 | — | — | US | claimed |
| EP-0299449-A2 | Pyridazinone, triazinone and oxapyridazinone lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1989-01-18 | — | — | EP | claimed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-7132441-B2 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | G.D. SEARLE & CO. (US) | 2006-11-07 | — | — | US | disclosed |
| US-6376528-B1 | SYNERGISTIC MIXTURE | G. D. SEARLE & CO. | 2002-04-23 | — | — | US | disclosed |
| US-5086052-A | Antiarthritic, antiallergens, antiinflammatory agents; also for asthma and psoriasis | ABBOTT LABORATORIES (US) | 1992-02-04 | — | — | US | disclosed |
| US-4970210-A | ENZYME INHIBITORS | ABBOTT LABORATORIES (US) | 1990-11-13 | — | — | US | disclosed |
| EP-0299449-A2 | Pyridazinone, triazinone and oxapyridazinone lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | ALOX5 25/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | ALOX5 25/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | ALOX5 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.